{"id":"autologous-serum-50","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection risk (contamination during preparation)"},{"rate":null,"effect":"Irritation or discomfort at application site"},{"rate":null,"effect":"Allergic reaction to serum components"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This preparation uses the patient's own serum, which contains endogenous growth factors, cytokines, and other bioactive molecules that promote epithelial regeneration and wound healing. When applied as eye drops or topical treatment, these autologous factors reduce inflammation and support tissue remodeling. The mechanism relies on the natural healing properties present in the patient's own blood rather than a synthetic pharmacological target.","oneSentence":"Autologous serum 50% is a patient's own blood serum diluted to 50% concentration, applied topically to provide growth factors and immunomodulatory components for tissue repair and healing.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:09.063Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye syndrome / Ocular surface disease"},{"name":"Corneal epithelial defects"}]},"trialDetails":[{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT07413172","phase":"PHASE2","title":"Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-03","conditions":"Dry Eye, Eye Diseases, Eyes Dry Chronic","enrollment":20},{"nctId":"NCT05857371","phase":"PHASE2","title":"Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy","status":"RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2024-03-13","conditions":"Urethral Stenosis","enrollment":20},{"nctId":"NCT06726538","phase":"PHASE1, PHASE2","title":"Investigating the Efficacy of Autologous, Adipose-derived Mesenchymal Stem Cell Therapy for the Treatment of Sexual Function Impairment in Women Aged 40-50","status":"COMPLETED","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2023-10-01","conditions":"Female Sexual Dysfunction","enrollment":50},{"nctId":"NCT03233152","phase":"PHASE1, PHASE2","title":"A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2016-11-17","conditions":"Glioblastoma","enrollment":110},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":231},{"nctId":"NCT02722668","phase":"PHASE2","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-05-15","conditions":"Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma","enrollment":15},{"nctId":"NCT03477500","phase":"PHASE3","title":"Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2018-03-21","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT04168502","phase":"PHASE3","title":"Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML","status":"RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2020-09-24","conditions":"Acute Myeloid Leukemia","enrollment":414},{"nctId":"NCT03182426","phase":"PHASE1, PHASE2","title":"Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2017-08-15","conditions":"Diabetes Mellitus, Type 1","enrollment":22},{"nctId":"NCT03310619","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-12-20","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular","enrollment":62},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT04683796","phase":"PHASE3","title":"Comparison of Efficacy Between 100% Platelet-rich Plasma and 100% Serum Eye Drops in Dry Eye Disease","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2021-02-01","conditions":"Dry Eye Disease","enrollment":96},{"nctId":"NCT02366728","phase":"PHASE2","title":"DC Migration Study for Newly-Diagnosed GBM","status":"COMPLETED","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","startDate":"2015-10-12","conditions":"Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma","enrollment":64},{"nctId":"NCT05200312","phase":"PHASE2","title":"A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-02-01","conditions":"Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":36},{"nctId":"NCT02677155","phase":"PHASE2","title":"Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2016-01","conditions":"Follicular Lymphoma","enrollment":10},{"nctId":"NCT00004031","phase":"PHASE3","title":"SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1997-07","conditions":"Lymphoma","enrollment":397},{"nctId":"NCT00076752","phase":"PHASE2","title":"Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-01-30","conditions":"Lupus Erythematosus, Systemic","enrollment":9},{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT00303719","phase":"PHASE2","title":"Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-03-26","conditions":"Kidney Cancer, Leukemia, Lymphoma","enrollment":342},{"nctId":"NCT03178695","phase":"PHASE1","title":"Inovium Ovarian Rejuvenation Trials","status":"COMPLETED","sponsor":"Ascendance Biomedical","startDate":"2017-06-01","conditions":"Perimenopausal Disorder, Menopause, Menopause, Premature","enrollment":200},{"nctId":"NCT02589145","phase":"PHASE1, PHASE2","title":"Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"Lymphoma","enrollment":8},{"nctId":"NCT00646854","phase":"PHASE3","title":"Alemtuzumab and CHOP in T-cell Lymphoma","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2008-06","conditions":"Lymphoma, T-Cell, Peripheral","enrollment":136},{"nctId":"NCT03666884","phase":"PHASE4","title":"The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome","status":"COMPLETED","sponsor":"Seref istek","startDate":"2015-10-10","conditions":"Dry Eye Syndrome","enrollment":36},{"nctId":"NCT03436576","phase":"PHASE3","title":"Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2018-09-12","conditions":"Dry Eye, Keratoconjunctivitis Sicca, Sjogren's Syndrome","enrollment":20},{"nctId":"NCT00482053","phase":"PHASE2","title":"Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT","status":"TERMINATED","sponsor":"Stanford University","startDate":"2006-10","conditions":"Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":3},{"nctId":"NCT01453205","phase":"PHASE2","title":"A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2012-02-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":187},{"nctId":"NCT00481832","phase":"PHASE2","title":"Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":50},{"nctId":"NCT00899847","phase":"PHASE2","title":"Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-05","conditions":"Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma","enrollment":9},{"nctId":"NCT00719849","phase":"PHASE2","title":"Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2005-11","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":13},{"nctId":"NCT02194374","phase":"PHASE1","title":"Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-01","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00020943","phase":"PHASE2","title":"Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-06","conditions":"Lymphoma","enrollment":79},{"nctId":"NCT00833534","phase":"PHASE2","title":"Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-02","conditions":"Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT00787761","phase":"PHASE2","title":"Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2007-04","conditions":"Myeloproliferative Disorders, Kidney Cancer, Leukemia","enrollment":24},{"nctId":"NCT00107614","phase":"PHASE2","title":"DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2002-11","conditions":"Waldenstrom Macroglobulinemia","enrollment":12},{"nctId":"NCT00499018","phase":"PHASE3","title":"Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2006-01","conditions":"Diffuse Large B-Cell Lymphoma, IPI≥2","enrollment":399},{"nctId":"NCT00946374","phase":"PHASE2","title":"Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2004-07","conditions":"Mantle-Cell Lymphoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Autologus serum high concentration"],"phase":"phase_3","status":"active","brandName":"Autologous Serum 50%","genericName":"Autologous Serum 50%","companyName":"Pontificia Universidad Catolica de Chile","companyId":"pontificia-universidad-catolica-de-chile","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Autologous serum 50% is a patient's own blood serum diluted to 50% concentration, applied topically to provide growth factors and immunomodulatory components for tissue repair and healing. Used for Dry eye syndrome / Ocular surface disease, Corneal epithelial defects.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}